Weitao Biotech (operating as IQVIA Biotech) functions as a specialized, full-service contract research organization (CRO) supporting biotech and biopharmaceutical companies globally. It provides clinical development solutions and therapeutic expertise across various fields, including oncology, cell and gene therapy, central nervous system studies, cardiovascular, renal and metabolic diseases, dermatology, and internal medicine.
Subscribe to see Weitao Biotech’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Weitao Biotech is a biotechnology company. Its most recent funding round, Series A, raised $50M in April 2026. Xcout tracks 10 named people at Weitao Biotech, including Peter Ronco (President).
4 more named people on record for Weitao Biotech, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $50M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Weitao Biotech's closest competitors — see the full list of competitors and alternatives →
Worldwide Clinical Trials is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology companies. The company offers end-to-end solutions, including early and late phase clinical trials, bioanalytical laboratory services, data management, and consulting across various therapeutic areas such as oncology, neuroscience, and rare diseases.
WuXi Biology provides a comprehensive spectrum of preclinical biology services and solutions for drug discovery, supporting clients from target discovery and validation to hit finding, lead optimization, and candidate selection. The company offers specialized platforms and expertise across major disease areas and therapeutic modalities, including small molecules, oligonucleotides, peptides, and antibodies.
Vivo Bio Tech Limited is an India-based contract research organization that provides preclinical drug-discovery and development services, including in-vivo pharmacology, toxicology, and related bioanalytical work. It serves pharmaceutical and biotechnology companies developing drugs and other healthcare products.
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
Crown Bioscience is a global contract research organization (CRO) headquartered in California that specializes in translational oncology and immuno-oncology drug discovery and development. The company provides comprehensive discovery, preclinical, and translational research platforms.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Weitao Biotech? Suggest a correction · Work at Weitao Biotech? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.